Unternehmen wird geladen
Just reported
Q3 2026 results
From Certara's results release of 5. November 2026; its quarterly report has since been filed.
Revenue
Actual
94,9M $
+4,4 % y/y
+1,7 % q/qGuided
—
No guide given
EPS, GAAP
Actual
0,04 $
+300 % y/y
Guided
—
No guide given
EPS, adjusted: 0,09 $
Operating income, GAAP
Actual
2,3M $
Guided
—
No guide given
Company outlook
Full year 2026
- EPS, adjusted0,31 $ – 0,34 $Lowered -3,0 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Certara is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.49,4B $A+
BTSGBrightSpring Health Services, Inc.14,4B $A
HNGEHinge Health, Inc.9,9B $A+
HQYHealthequity, Inc.8,5B $A+
DOCSDoximity, Inc.5,9B $B+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
Gebaut aus den eigenen Einreichungen von Certara, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
